A recent study published in eGastroenterology introduces young rabbits with CF as a novel and accessible model to study ...
SIL-204 administered in an extended release formulation reduced tumor growth by ~50% after 30 days, with ~50% of tumors ...
Pluristyx has developed a clinical-grade manufacturing process for using a licensed Mad7 gene editing technology to block Human Leukocyte Antigen (HLA) markers expression. Humacyte is optimizing a ...
Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction representing a critical and ...
GI Innovation (KQ:358570) announced that it signed a Memorandum of Understanding (MOU) with LaNova Medicines (LaNova) for the ...